- Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire
- Breast cancer drug Nerlynx gets TGA approval The Australian
- Breast cancer drug approved for Australia PerthNow
- View full coverage on Google News
Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer – Business Wire
ByGoogle News
Mar 18, 2019